Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
University of Miami
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
St. Jude Children's Research Hospital
Dartmouth-Hitchcock Medical Center
Children's Hospital Medical Center, Cincinnati
M.D. Anderson Cancer Center
Center for International Blood and Marrow Transplant Research
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
City of Hope Medical Center
University of Michigan Rogel Cancer Center
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Center for International Blood and Marrow Transplant Research
Ohio State University Comprehensive Cancer Center
Janssen Research & Development, LLC
M.D. Anderson Cancer Center
Incyte Corporation
Rigshospitalet, Denmark
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Arizona
City of Hope Medical Center
Case Comprehensive Cancer Center
University of Arizona
M.D. Anderson Cancer Center
Thomas Jefferson University
Thomas Jefferson University
Baylor College of Medicine
UNC Lineberger Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Incyte Corporation
University of Wisconsin, Madison
Janssen Research & Development, LLC
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Stanford University
St. Jude Children's Research Hospital
Massachusetts General Hospital
Baylor College of Medicine
Barbara Ann Karmanos Cancer Institute